Study #2017-0243
A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in Previously Treated AL Amyloidosis
MD Anderson Study Status
Not Accepting
Treatment Agent
Daratumumab, Dexamethasone, Ixazomib
Description
This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab, ixazomib, and dexamethasone may be effective in treating participants with light chain amyloidosis.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Study phase:
Phase I
Physician name:
Hans Lee
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-855-773-0951
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.